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The Authors Reply: We appreciate the comments by Nakao
et al.1 in response to our publication.2 In keeping with our
results, their historical control study did not find any
reduction of peritonitis rate after the introduction of
biocompatible solutions. But, the most outstanding aspect
to their report is the fact that their peritonitis rate was
between 1 in 144 and 1 in 173 patient-months! With such
excellent results, it is perhaps unrealistic to expect further
reduction in peritonitis rate. Moreover, it is unclear from
their letter whether all prevalent patients were switched to
biocompatible solutions after April 2005 or whether only new
incident patients were started on the newer solutions. If the
latter is true, then an immediate reduction in overall
peritonitis rate cannot be expected.
However, their ﬁnding of the bacterial species causing
peritonitis change is intriguing. It raises several possibilities.
Such a change may be unrelated to the introduction of
biocompatible solutions; perhaps, there were other changes
in clinical practice over the years. Equally, it is possible that
they have noticed a change in the organisms causing
peritonitis because of their very low infection rate—in our
study, any impact of biocompatible solutions may have been
overwhelmed by the high ‘bacterial burden’ experienced by
our patients. To address this possibility, we have reanalyzed
our data but selecting only patients with low risk of
peritonitis.
We somewhat arbitrarily deﬁned low-risk patients to be
aged o55 years, non-diabetic, and non-HIV. These patients
had a peritonitis rate of 1 in 37.7 vs. 1 in 40.0 patient-months
(standard vs. conventional, P¼ nonsigniﬁcant by w2). How-
ever, the proportion of patients with Gram-positive peritonitis
was higher in the biocompatible group (30 out of 41
infections) than in the standard group (15 in 31 infections).
This would appear to have reached statistical signiﬁcance
(P¼ 0.03 by w2). However, this was not a prespeciﬁed
secondary end point, and achieving a P-value of o0.05 after
multiple analysis of data is unlikely to be signiﬁcant.
Moreover, Nakao found the opposite, i.e., after biocompatible
solutions were introduced, they found that peritonitis from
Gram-negative organisms increased.
Perhaps, we can only safely conclude that we must be
cautious when interpreting historical-controlled studies or
when performing multiple non-prespeciﬁed analyses of data.
One hopes that the large multicenter Australian/New
Zealand/South East Asia balANZ study that has been pre-
sented, but not yet published, will provide a more deﬁnitive
answer to the hypothesis raised by Nakao et al.1
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